LU91663I2 - Simponi-Golimumab - Google Patents

Simponi-Golimumab

Info

Publication number: LU91663I2
Authority: LU; Luxembourg
Prior art keywords: methods; simponi; golimumab; tnf; tnf antibody
Prior art date: 2000-08-07

Application number

LU91663C

Other languages

English (en)

Other versions

LU91663I9 (fr

Original Assignee

Centocor Ortho Biotech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-07

Filing date

2010-03-12

Publication date

2010-05-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40673117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91663(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-03-12 Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc

2010-05-12 Publication of LU91663I2 publication Critical patent/LU91663I2/fr

2018-12-18 Publication of LU91663I9 publication Critical patent/LU91663I9/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

LU91663C 2000-08-07 2010-03-12 Simponi-Golimumab LU91663I2 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US22336000P	2000-08-07	2000-08-07
US23682600P	2000-09-29	2000-09-29
US09/920,137 US7250165B2 (en)	2000-08-07	2001-08-01	Anti-TNF antibodies, compositions, methods and uses
PCT/US2001/024785 WO2002012502A2 (fr)	2000-08-07	2001-08-07	Anticorps anti-tnf, compositions, methodes et utilisations

Publications (2)

Publication Number	Publication Date
LU91663I2 true LU91663I2 (fr)	2010-05-12
LU91663I9 LU91663I9 (fr)	2018-12-18

Family

ID=40673117

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
LU91663C LU91663I2 (fr)	2000-08-07	2010-03-12	Simponi-Golimumab
LU00010C LUC00010I2 (fr)	2000-08-07	2017-03-10
LU00121C LUC00121I2 (fr)	2000-08-07	2019-05-23

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
LU00010C LUC00010I2 (fr)	2000-08-07	2017-03-10
LU00121C LUC00121I2 (fr)	2000-08-07	2019-05-23

Country Status (33)

Country	Link
US (3)	US7250165B2 (fr)
EP (4)	EP3118318B1 (fr)
JP (7)	JP4748920B2 (fr)
KR (1)	KR100883078B1 (fr)
CN (2)	CN101980017B (fr)
AT (1)	ATE446367T1 (fr)
AU (2)	AU7922701A (fr)
BE (1)	BE2010C014I2 (fr)
BR (1)	BRPI0113110C8 (fr)
CA (1)	CA2419205C (fr)
CY (7)	CY1109618T1 (fr)
DE (2)	DE122010000010I1 (fr)
DK (4)	DK1309691T3 (fr)
EA (2)	EA007005B1 (fr)
ES (4)	ES2709335T3 (fr)
FR (1)	FR10C0014I2 (fr)
HK (1)	HK1052948B (fr)
HR (1)	HRP20030089B1 (fr)
HU (2)	HU229523B1 (fr)
IL (3)	IL154327A0 (fr)
LT (5)	LT2330129T (fr)
LU (3)	LU91663I2 (fr)
ME (1)	ME00314B (fr)
MX (1)	MXPA03001231A (fr)
MY (2)	MY157288A (fr)
NO (3)	NO333378B1 (fr)
NZ (2)	NZ562811A (fr)
PL (1)	PL206833B1 (fr)
PT (4)	PT2330129T (fr)
RS (1)	RS50858B (fr)
SI (4)	SI3118318T1 (fr)
UA (1)	UA81743C2 (fr)
WO (1)	WO2002012502A2 (fr)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
US6258562B1 (en) *	1996-02-09	2001-07-10	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
US7163681B2 (en) *	2000-08-07	2007-01-16	Centocor, Inc.	Anti-integrin antibodies, compositions, methods and uses
US6709655B2 (en) *	2001-02-28	2004-03-23	Instituto Bioclon, S.A. De C.V.	Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
CA2385745C (fr)	2001-06-08	2015-02-17	Abbott Laboratories (Bermuda) Ltd.	Methodes pour administrer des anticorps anti-tnf.alpha.
TWI334439B (en)	2001-08-01	2010-12-11	Centocor Inc	Anti-tnf antibodies, compositions, methods and uses
AU2002351957B2 (en) *	2001-11-12	2009-09-03	Merck Patent Gmbh	Modified anti-TNF alpha antibody
AU2002359495A1 (en) *	2001-11-30	2003-06-17	Centocor, Inc.	Anti-tnf antibodies, compositions, methods and uses
US20040009172A1 (en) *	2002-04-26	2004-01-15	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
EP1600459A3 (fr) *	2002-06-28	2005-12-07	Domantis Limited	Ligand
EP2322559A3 (fr)	2002-07-04	2011-08-03	Patrys Limited	Anticorps specifiques de neoplasme et utilisations associees
BR0312785A (pt) *	2002-07-19	2005-08-30	Abbott Biotech Ltd	Tratamento de desordens relacionadas a tnf(alfa)
US20040033228A1 (en)	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en)	2002-10-24	2014-02-28	Abbvie Biotechnology Ltd	Low dose methods for treating disorders in which tnf? activity is detrimental
JP2006520584A (ja)	2002-11-08	2006-09-14	アブリンクスエン．ヴェー．	安定化単一ドメイン抗体
US9320792B2 (en)	2002-11-08	2016-04-26	Ablynx N.V.	Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en)	2002-11-08	2006-02-16	Karen Silence	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US7335759B2 (en) *	2002-12-02	2008-02-26	Universidad Nacional Autónoma de Méxica (UNAM)	Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
EP1578799B8 (fr)	2002-12-02	2011-03-23	Amgen Fremont Inc.	Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisations
US7101978B2 (en)	2003-01-08	2006-09-05	Applied Molecular Evolution	TNF-α binding molecules
DE10311248A1 (de)	2003-03-14	2004-09-30	Müller-Hermelink, Hans Konrad, Prof. Dr.	Humaner monoklonaler Antikörper
MXPA06000965A (es) *	2003-07-25	2007-05-04	Silanes Sa De Cv Lab	Administracion de fragmentos f(ab??)2 de anticuerpos anti-citocinas.
US20070110750A1 (en) *	2003-09-12	2007-05-17	The Regents Of The University Of California	Monoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
CN1328379C (zh) *	2003-11-13	2007-07-25	中国人民解放军第四军医大学	高亲和力抗肿瘤坏死因子单克隆抗体的可变区基因
DE10353175A1 (de)	2003-11-14	2005-06-16	Müller-Hermelink, Hans Konrad, Prof. Dr.	Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (fr)	2003-11-14	2005-05-18	Heinz Vollmers	Anticorps SAM-6, spécifique d'adénocarcinome, et ses utilisations
US7435799B2 (en)	2004-01-08	2008-10-14	Applied Molecular Evolution	TNF-α binding molecules
RS51908B (sr) *	2004-02-06	2012-02-29	University of Massachusetts	Antitela protiv toksina clostridium difficile i njihove primene
TWI556829B (zh)	2004-04-09	2016-11-11	艾伯維生物技術有限責任公司	用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en)	2004-06-23	2004-07-28	Owen Mumford Ltd	Improvements relating to automatic injection devices
WO2006039638A2 (fr) *	2004-09-30	2006-04-13	Centocor, Inc.	Traitement d'un hypernephrome avec un anticorps humain anti-tnf ou un fragment de cet anticorps
EP1807111A4 (fr) *	2004-10-08	2009-05-27	Abbott Biotech Ltd	Infection a virus respiratoire syncytial (rsv)
GB0425972D0 (en) *	2004-11-25	2004-12-29	Celltech R&D Ltd	Biological products
DK1839120T3 (da) *	2004-12-21	2013-11-11	Janssen Biotech Inc	Vektorer baseret på Anti-IL-12-antistoffer, værtsceller og fremgangsmåder til fremstilling og anvendelser
US7381802B2 (en) *	2005-04-15	2008-06-03	Universidad Nacional Autónoma De México (UNAM)	Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
MX2007014440A (es)	2005-05-16	2008-02-11	Abbott Biotech Ltd	Uso de inhibidor de tnf para tratamiento de poliartritis erosiva.
US20070041905A1 (en) *	2005-08-19	2007-02-22	Hoffman Rebecca S	Method of treating depression using a TNF-alpha antibody
JP2009508476A (ja)	2005-08-31	2009-03-05	セントカー・インコーポレーテツド	高められたエフェクター機能をもつ抗体定常領域の製造用の宿主細胞株
HRP20131112T1 (hr)	2005-11-01	2014-01-03	Abbvie Biotechnology Ltd	Postupak za odreä�ivanje uäśinkovitosti adalimumaba kod subjekata koji pate od ankilozantnog spondilitisa pomoä†u ctx-ii i mmp3 kao biomarkera
SG170837A1 (en)	2006-04-05	2011-05-30	Abbott Biotech Ltd	Antibody purification
EP2666478A3 (fr)	2006-04-10	2014-10-22	AbbVie Biotechnology Ltd	Utilisations et compositions pour le traitement du psoriasis
CA2564435A1 (fr)	2006-04-10	2007-10-10	Abbott Biotechnology Ltd.	Methodes de controle et de traitement des troubles intestinaux
US20090317399A1 (en) *	2006-04-10	2009-12-24	Pollack Paul F	Uses and compositions for treatment of CROHN'S disease
EP2007426A4 (fr)	2006-04-10	2010-06-16	Abbott Biotech Ltd	Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
EP2010213A4 (fr) *	2006-04-10	2010-08-11	Abbott Biotech Ltd	Utilisation et compositions pour le traitement de l'arthrite rhumatoïde juvénile
EP2010214A4 (fr) *	2006-04-10	2010-06-16	Abbott Biotech Ltd	Utilisations et compositions pour le traitement de la polyarthrite rhumatoïde
WO2007120626A2 (fr)	2006-04-10	2007-10-25	Abbott Biotechnology Ltd.	Utilisations et compositions pour le traitement de la spondylarthrite ankylosante
US9605064B2 (en)	2006-04-10	2017-03-28	Abbvie Biotechnology Ltd	Methods and compositions for treatment of skin disorders
US20080118496A1 (en) *	2006-04-10	2008-05-22	Medich John R	Uses and compositions for treatment of juvenile rheumatoid arthritis
US20080131374A1 (en) *	2006-04-19	2008-06-05	Medich John R	Uses and compositions for treatment of rheumatoid arthritis
US20100021451A1 (en)	2006-06-08	2010-01-28	Wong Robert L	Uses and compositions for treatment of ankylosing spondylitis
CN107243099A (zh)	2006-06-30	2017-10-13	艾伯维生物技术有限公司	自动注射装置
US8911964B2 (en)	2006-09-13	2014-12-16	Abbvie Inc.	Fed-batch method of making human anti-TNF-alpha antibody
TWI548747B (zh) *	2006-09-13	2016-09-11	艾伯維有限公司	細胞培養改良
JP2010507670A (ja)	2006-10-27	2010-03-11	アボツト・バイオテクノロジー・リミテツド	結晶性抗ｈＴＮＦα抗体
WO2008092084A2 (fr) *	2007-01-26	2008-07-31	Centocor, Inc.	Suspension non aqueuse injectable présentant une concentration élevée en agent thérapeutique
JP2010523695A (ja) *	2007-04-11	2010-07-15	アルコンリサーチ，リミテッド	アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのＴＮＦαのインヒビターおよび抗ヒスタミン薬の使用
US8092998B2 (en)	2007-05-31	2012-01-10	Abbott Laboratories	Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
EP2171451A4 (fr)	2007-06-11	2011-12-07	Abbott Biotech Ltd	Procédés de traitement de l'arthrite idiopathique juvénile
US20090110679A1 (en) *	2007-07-13	2009-04-30	Luk-Chiu Li	Methods and compositions for pulmonary administration of a TNFa inhibitor
MX2010001488A (es)	2007-08-08	2010-03-01	Abbott Lab	Composiciones y metodos para cristalizar anticuerpos.
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
KR20210049186A (ko) *	2007-11-30	2021-05-04	애브비 바이오테크놀로지 리미티드	단백질 제형 및 이의 제조방법
NZ621174A (en)	2008-01-15	2015-09-25	Abbvie Deutschland	Powdered protein compositions and methods of making same
CA2717905A1 (fr) *	2008-03-24	2009-10-01	Abbott Biotechnology Ltd.	Compositions et methodes de traitement de la perte osseuse
US11969501B2 (en)	2008-04-21	2024-04-30	Dompé Farmaceutici S.P.A.	Auris formulations for treating otic diseases and conditions
KR102340754B1 (ko)	2008-04-21	2021-12-16	오토노미, 인코포레이티드	귀 질환 및 병태를 치료하기 위한 귀 조제물
JP2011524741A (ja) *	2008-05-27	2011-09-08	協和発酵キリン株式会社	インターロイキン１０受容体（ｉｌ−１０ｒ）抗体及び使用方法
RU2652907C2 (ru) *	2008-06-25	2018-05-03	ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи	Гуманизация антител кролика с использованием универсального каркаса антитела
ES2677003T3 (es)	2008-06-25	2018-07-27	Esbatech, An Alcon Biomedical Research Unit Llc	Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos
CA2731769C (fr)	2008-07-21	2013-09-10	Otonomy, Inc.	Compositions a liberation controlee modulant la structure otique et modulant le systeme immunitaire naturel et procedes de traitement de troubles otiques
US8784870B2 (en) *	2008-07-21	2014-07-22	Otonomy, Inc.	Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US20110251099A1 (en)	2008-12-30	2011-10-13	Sudha Visvanathan	SERUM MARKERS PREDICTING CLINICAL RESPONSE TO ANTI-TNFa ANTIBODIES IN PATIENTS WITH ANKYLOSING SPONDYLITIS
NZ595885A (en)	2009-04-29	2014-05-30	Abbvie Biotechnology Ltd	Automatic injection device
CN102458469B (zh) *	2009-05-04	2014-12-24	艾伯维生物技术有限公司	人抗TNF-α抗体的稳定高蛋白质浓度制剂
JP2012526840A (ja) *	2009-05-13	2012-11-01	プロテインデリヴァリーソリューションズエルエルシー	膜貫通送達のための製剤系
CA2773483A1 (fr) *	2009-10-01	2011-04-07	Alcon Research, Ltd.	Compositions d'olopatadine et leurs utilisations
CN104634955B (zh) *	2009-10-26	2016-09-14	雀巢产品技术援助有限公司	检测抗-tnf药物和自身抗体的试验
US8389689B2 (en)	2009-10-28	2013-03-05	Janssen Biotech, Inc.	Anti-GLP-1R antibodies and their uses
UY32979A (es) *	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2010330907A1 (en)	2009-12-16	2012-06-14	Bosch, Phillip	Methods of treating interstitial cystitis
CL2010000019A1 (es) *	2010-01-11	2010-06-11	Univ Chile	Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion.
CA2789168A1 (fr)	2010-02-02	2011-08-11	Abbott Biotechnology Ltd.	Procedes et compositions de prediction de la reponse a un traitement avec un inhibiteur du tnf-.alpha.
WO2011095174A1 (fr)	2010-02-08	2011-08-11	Aarhus Universitet	Polypeptides et polynucléotides u20 des virus de l'herpès humain 6 et 7 pour une utilisation en tant que médicament ou diagnostic
CN102167741B (zh) *	2010-02-25	2014-05-14	上海百迈博制药有限公司	一种全人源抗TNF-α单克隆抗体、其制备方法及用途
US20110223208A1 (en) *	2010-03-09	2011-09-15	Beth Hill	Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9072668B2 (en)	2010-03-09	2015-07-07	Janssen Biotech, Inc.	Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
NZ602782A (en)	2010-04-21	2015-07-31	Abbvie Biotechnology Ltd	Wearable automatic injection device for controlled delivery of therapeutic agents
US20110287018A1 (en)	2010-05-19	2011-11-24	Philip Bosch	Methods of Treating Interstitial Cystitis
CN103079594B (zh)	2010-06-03	2016-04-13	艾伯维生物技术有限公司	用于治疗化脓性汗腺炎(hs)的用途和组合物
PE20131412A1 (es)	2010-08-03	2014-01-19	Abbvie Inc	Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2011325974B2 (en)	2010-11-11	2016-10-27	Abbvie Biotechnology Ltd.	Improved high concentration anti-TNFalpha antibody liquid formulations
EP2490024A1 (fr)	2010-12-22	2012-08-22	Proteomika, S.L.	Procédé pour optimiser le traitement de patients au moyen de médicaments biologiques
EP2471554A1 (fr)	2010-12-28	2012-07-04	Hexal AG	Formulation pharmaceutique comprenant un médicament biopharmaceutique
WO2012103141A1 (fr)	2011-01-24	2012-08-02	Abbott Biotechnology Ltd.	Dispositifs d'injection automatique dotés de surfaces de préhension surmoulées
CN102675460B (zh) *	2011-02-28	2015-08-19	珠海市丽珠单抗生物技术有限公司	抗肿瘤坏死因子α的人源化抗体
WO2012129174A1 (fr)	2011-03-18	2012-09-27	Abbott Laboratories	Systèmes, dispositifs et procédés pour assembler des dispositifs à injection automatique et des sous-ensembles leur correspondant
CN105413022A (zh)	2011-03-29	2016-03-23	艾伯维公司	自动注射装置中的改进的护罩展开
MX345747B (es)	2011-04-21	2017-02-14	Abbvie Inc	Dispositivo de inyección automático portable.
WO2012149197A2 (fr)	2011-04-27	2012-11-01	Abbott Laboratories	Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
WO2013158273A1 (fr)	2012-04-20	2013-10-24	Abbvie Inc.	Procédés de modulation de la distribution de variant de lysine c-terminal
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
EP2890782A1 (fr)	2012-09-02	2015-07-08	AbbVie Inc.	Procédés de contrôle de l'hétérogénéité des protéines
PE20150964A1 (es)	2012-09-07	2015-07-25	Coherus Biosciences Inc	Formulaciones acuosas estables de adalimumab
KR20150056788A (ko) *	2012-09-19	2015-05-27	애브비 바이오테라퓨틱스 인크.	면역원성이 감소된 항체의 동정 방법
KR20190096459A (ko)	2012-11-01	2019-08-19	애브비 인코포레이티드	항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
CN105121460A (zh) *	2013-03-06	2015-12-02	波塔力克斯有限公司	表达TNFα多肽抑制的植物细胞在治疗中的用途
US20160017021A1 (en)	2013-03-06	2016-01-21	Protalix Ltd.	TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
EP2830651A4 (fr)	2013-03-12	2015-09-02	Abbvie Inc	Anticorps humains qui se lient au tnf-alpha et leurs procédés de préparation
US8921526B2 (en)	2013-03-14	2014-12-30	Abbvie, Inc.	Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (fr)	2013-03-14	2014-09-25	Abbvie Inc.	Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
BR112015023797A2 (pt)	2013-03-15	2017-10-24	Abbvie Inc	proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
ES2690047T3 (es)	2013-03-15	2018-11-19	Janssen Biotech, Inc.	Procedimientos de fabricación para controlar la lisina C-terminal, la galactosa y el contenido de ácido siálico en proteínas recombinantes
US9603775B2 (en)	2013-04-24	2017-03-28	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2015051293A2 (fr)	2013-10-04	2015-04-09	Abbvie, Inc.	Utilisation d'ions métalliques pour moduler les profils de glycosylation des protéines dans le cas de protéines recombinées
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (fr)	2013-11-15	2015-05-21	Abbvie, Inc.	Compositions de protéines de liaison génétiquement glycomodifiées
WO2015083765A1 (fr) *	2013-12-04	2015-06-11	国立大学法人大阪大学	Procédé permettant de prévoir l'effet thérapeutique d'une préparation biologique sur l'arthrite rhumatoïde
US20160367520A1 (en)	2014-02-10	2016-12-22	Patara Pharma, LLC	Mast cell stabilizers for lung disease treatment
EP3104853B1 (fr)	2014-02-10	2019-10-02	Respivant Sciences GmbH	Traitement utilisant des stabilisateurs de mastocytes pour des troubles systémiques
EP3145951A1 (fr)	2014-06-24	2017-03-29	InSight Biopharmaceuticals Ltd.	Procédés de purification d'anticorps
MX388301B (es)	2014-09-03	2025-03-19	Boehringer Ingelheim Int	Il-23a y tnf-alfa orientados y compuesto y sus usos.
US10000551B2 (en)	2014-09-11	2018-06-19	Protalix Ltd.	Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
IL254577B2 (en)	2015-03-31	2023-11-01	Vhsquared Ltd	polypeptides
CN107438620A (zh)	2015-03-31	2017-12-05	韦斯夸尔德有限公司	多肽
IL254589B2 (en)	2015-03-31	2023-11-01	Vhsquared Ltd	A peptide structure with a protease-cleavable linker
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017027402A1 (fr)	2015-08-07	2017-02-16	Patara Pharma, LLC	Méthodes de traitement de troubles systémiques aptes à être traités par des stabilisateurs de mastocytes, y compris de troubles liés aux mastocytes
WO2017027387A1 (fr)	2015-08-07	2017-02-16	Patara Pharma, LLC	Méthodes de traitement de troubles liés aux mastocytes par des stabilisateurs de mastocytes
US11229702B1 (en)	2015-10-28	2022-01-25	Coherus Biosciences, Inc.	High concentration formulations of adalimumab
GB201522394D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
MA46681A (fr) *	2016-01-28	2019-09-11	Janssen Biotech Inc	Anticorps bispécifiques anti-tnf-alpha/il-17a antibodies et anticorps anti-tnf-alpha et leurs procédés d'utilisation
US10465003B2 (en) *	2016-02-05	2019-11-05	Janssen Biotech, Inc.	Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
WO2017177179A1 (fr)	2016-04-08	2017-10-12	Gilead Sciences, Inc.	Compositions et méthodes de traitement du cancer, de maladies inflammatoires et de maladies autoimmunes
US11071782B2 (en)	2016-04-20	2021-07-27	Coherus Biosciences, Inc.	Method of filling a container with no headspace
US10858422B2 (en)	2016-05-31	2020-12-08	Abcentra, Llc	Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
EP3478269A4 (fr)	2016-06-29	2020-04-08	Otonomy, Inc.	Formulations otiques à base de triglycérides et leurs utilisations
WO2018044942A1 (fr)	2016-08-31	2018-03-08	Patara Pharma, LLC	Compositions de cromolyne pour le traitement de la toux chronique due à une fibrose pulmonaire idiopathique
EP3519438A1 (fr)	2016-09-30	2019-08-07	VHsquared Limited	Compositions
JP2019531308A (ja)	2016-10-07	2019-10-31	レシュピファントサイエンシスゲゼルシャフトミットベシュレンクターハフトゥングＲｅｓｐｉｖａｎｔＳｃｉｅｎｃｅｓＧｍｂｈ	肺線維症の治療のためのクロモリン組成物
EP3824906A1 (fr)	2016-12-21	2021-05-26	Amgen Inc.	Formulations d'anticorps anti-tnf alpha
JOP20190162A1 (ar)	2016-12-30	2019-06-27	Biocad Joint Stock Co	تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
CN110234351A (zh)	2017-01-30	2019-09-13	詹森生物科技公司	用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
CA3052578A1 (fr)	2017-02-07	2018-08-16	Janssen Biotech, Inc.	Anticorps anti-tnf, compositions et methodes pour le traitement de la spondylarthrite ankylosante active
CA3129373A1 (fr)	2018-05-29	2019-12-05	Abcentra, Llc	Compositions et procedes pour le traitement de la polyarthrite rhumatoide et de l'atherosclerose acceleree
JP7689074B2 (ja)	2019-01-15	2025-06-05	ヤンセンバイオテツク，インコーポレーテツド	若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
EA202192508A1 (ru)	2019-03-14	2022-03-29	Янссен Байотек, Инк.	Способы получения композиций антитела к фно
MA55282A (fr)	2019-03-14	2022-01-19	Janssen Biotech Inc	Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
JP7635137B2 (ja)	2019-03-14	2025-02-25	ヤンセンバイオテツク，インコーポレーテツド	抗ｔｎｆ抗体組成物を産生するための方法
JP7805788B2 (ja)	2019-05-23	2026-01-26	ヤンセンバイオテツク，インコーポレーテツド	Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
JP2022536279A (ja)	2019-06-03	2022-08-15	ヤンセンバイオテツク，インコーポレーテツド	乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
AU2020294980A1 (en)	2019-06-21	2022-02-17	Sorriso Pharmaceuticals, Inc.	Polypeptides
US20220242945A1 (en)	2019-06-21	2022-08-04	Sorriso Pharmaceuticals, Inc.	Polypeptides
WO2021028752A1 (fr)	2019-08-15	2021-02-18	Janssen Biotech, Inc.	Anticorps anti-tfn pour le traitement du diabète de type i
CN111153994B (zh) *	2019-12-31	2021-10-15	武汉班科生物技术股份有限公司	人肿瘤坏死因子的人源单克隆抗体
EP4126919A1 (fr) *	2020-03-24	2023-02-08	Bio-Techne Corporation	Méthodes d'utilisation d'une lignée cellulaire knock-out tgf-bêta et compositions obtenues à partir de celle-ci
MX2022014430A (es)	2020-05-21	2023-02-22	Janssen Biotech Inc	Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
CA3208791A1 (fr) *	2020-12-23	2022-06-30	Amgen Inc.	Procedes et systemes de selection de conditions pour preparer des formulations d'inhalation
US20220372129A1 (en)	2021-05-20	2022-11-24	Janssen Biotech, Inc.	Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF Alpha
AU2022308201A1 (en)	2021-07-09	2024-02-22	Janssen Biotech, Inc.	Manufacturing methods for producing anti-tnf antibody compositions
WO2023154799A1 (fr)	2022-02-14	2023-08-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Immunothérapie combinée pour traitement du cancer
WO2024054934A1 (fr)	2022-09-07	2024-03-14	Mdx Management Llc	Inhibiteurs de shp-1 pour le traitement du cancer
IL320590A (en)	2022-11-02	2025-07-01	Mdx Man Llc	Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for cancer treatment
EP4676531A1 (fr) *	2023-03-03	2026-01-14	Alvotech HF	Formulations liquides comprenant du golimumab et du poloxamère 188
WO2024196822A1 (fr)	2023-03-17	2024-09-26	Mdx Management Llc	Compositions et méthodes visant à atténuer les effets indésirables de thérapies
TW202508626A (zh)	2023-05-03	2025-03-01	美商健生生物科技公司	以針對ＩＬ－２３及ＴＮＦα的抗體的組合來治療克隆氏症之方法
WO2024228134A1 (fr)	2023-05-03	2024-11-07	Janssen Biotech, Inc.	Procédé de traitement de la colite ulcéreuse avec une combinaison d'anticorps contre il-23 et tnf alpha
WO2025038745A1 (fr)	2023-08-16	2025-02-20	Mdx Management Llc	Compositions et procédés pour activation de cellules immunitaires
WO2025049345A1 (fr)	2023-08-25	2025-03-06	Proteologix Us Inc.	Constructions d'anticorps multispécifiques anti-il-13 et leurs utilisations
WO2025099576A1 (fr)	2023-11-06	2025-05-15	Momenta Pharmaceuticals, Inc.	Compositions et méthodes de traitement de la polyarthrite rhumatoïde
WO2025188921A1 (fr)	2024-03-06	2025-09-12	Mdx Management Llc	Inhibiteurs de shp-1 et activateurs de lymphocytes t

Family Cites Families (189)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4309989A (en)	1976-02-09	1982-01-12	The Curators Of The University Of Missouri	Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr)	1976-10-23	1978-07-21	Choay Sa	Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
FR2413974A1 (fr)	1978-01-06	1979-08-03	David Bernard	Sechoir pour feuilles imprimees par serigraphie
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5700466A (en)	1981-09-08	1997-12-23	The Rockefeller University	Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US4603106A (en)	1982-02-22	1986-07-29	The Rockefeller University	Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4822776A (en)	1981-09-08	1989-04-18	The Rockefeller University	Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4656134A (en)	1982-01-11	1987-04-07	Board Of Trustees Of Leland Stanford Jr. University	Gene amplification in eukaryotic cells
US5149636A (en)	1982-03-15	1992-09-22	Trustees Of Columbia University In The City Of New York	Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en)	1986-08-22	1990-10-23	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US6492107B1 (en)	1986-11-20	2002-12-10	Stuart Kauffman	Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
WO1986005803A1 (fr)	1985-03-30	1986-10-09	Marc Ballivet	Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn
SE448277B (sv)	1985-04-12	1987-02-09	Draco Ab	Indikeringsanordning vid en doseringsanordning for lekemedel
US4766067A (en)	1985-05-31	1988-08-23	President And Fellows Of Harvard College	Gene amplification
GB8517895D0 (en)	1985-07-16	1985-08-21	Technology Licence Co Ltd	Monoclonal antibodies
EP0212489B1 (fr)	1985-08-16	1994-11-30	The Rockefeller University	Modulateur de l'activité anabolique et ses applications
US4870163A (en)	1985-08-29	1989-09-26	New York Blood Center, Inc.	Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5576195A (en)	1985-11-01	1996-11-19	Xoma Corporation	Vectors with pectate lyase signal sequence
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de)	1986-01-15	1987-07-16	Ant Nachrichtentech	Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4800159A (en)	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
SE453566B (sv)	1986-03-07	1988-02-15	Draco Ab	Anordning vid pulverinhalatorer
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4767402A (en)	1986-07-08	1988-08-30	Massachusetts Institute Of Technology	Ultrasound enhancement of transdermal drug delivery
IL79740A0 (en)	1986-08-17	1986-11-30	Yeda Res & Dev	Hepatitis vaccine
WO1988001213A1 (fr)	1986-08-18	1988-02-25	Clinical Technologies Associates, Inc.	Systemes de distribution pour agents pharmacologiques
US4889818A (en)	1986-08-22	1989-12-26	Cetus Corporation	Purified thermostable enzyme
US4704692A (en)	1986-09-02	1987-11-03	Ladner Robert C	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
DE3631229A1 (de)	1986-09-13	1988-03-24	Basf Ag	Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US4921794A (en)	1987-01-14	1990-05-01	President And Fellows Of Harvard College	T7 DNA polymerase
US4795699A (en)	1987-01-14	1989-01-03	President And Fellows Of Harvard College	T7 DNA polymerase
EP0279582A3 (fr)	1987-02-17	1989-10-18	Pharming B.V.	Séquences d'ADN pour diriger des protéines vers les glandes mammaires afin d'être sécrétées efficacement
EP0349578B2 (fr)	1987-03-02	1998-10-28	Enzon Labs Inc.	Organism ayant un "Single Chain Antibody Domain (SCAD)" á l'exterieur.
JP2647427B2 (ja)	1987-04-24	1997-08-27	帝人株式会社	被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
US4873316A (en)	1987-06-23	1989-10-10	Biogen, Inc.	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
CA1341235C (fr)	1987-07-24	2001-05-22	Randy R. Robinson	Assemblage modulaire de genes d'anticorps, anticorps prepares de cette facon, ainsi que leur usage
US4939666A (en)	1987-09-02	1990-07-03	Genex Corporation	Incremental macromolecule construction methods
IL83878A (en)	1987-09-13	1995-07-31	Yeda Res & Dev	Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
CA1338518C (fr)	1987-09-23	1996-08-13	Joyce M. Zarling	Heteroconjugues d'anticorps pour tuer les cellules infectees par le vih
ATE140731T1 (de)	1988-01-11	1996-08-15	Xoma Corp	Plasmidvektor mit pectatlyase-signalsequenz
US6010902A (en)	1988-04-04	2000-01-04	Bristol-Meyers Squibb Company	Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US4956288A (en)	1988-04-22	1990-09-11	Biogen, Inc.	Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5770198A (en)	1988-05-18	1998-06-23	The Research Foundation Of The State Of New York	Platelet-specific chimeric 7E3 immunoglobulin
US5130238A (en)	1988-06-24	1992-07-14	Cangene Corporation	Enhanced nucleic acid amplification process
DE3823804A1 (de)	1988-07-14	1990-01-18	Basf Ag	Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten
WO1990000902A1 (fr)	1988-07-18	1990-02-08	Chiron Corporation	Anticorps monoclonaux reagissant avec la cachetine
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
IL94039A (en)	1989-08-06	2006-09-05	Yeda Res & Dev	Antibodies to tbp - 1 and their use
US5142033A (en)	1988-09-23	1992-08-25	Hoffmann-La Roche Inc.	Structure-independent DNA amplification by the polymerase chain reaction
US5091310A (en)	1988-09-23	1992-02-25	Cetus Corporation	Structure-independent dna amplification by the polymerase chain reaction
US5066584A (en)	1988-09-23	1991-11-19	Cetus Corporation	Methods for generating single stranded dna by the polymerase chain reaction
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US4987893A (en)	1988-10-12	1991-01-29	Rochal Industries, Inc.	Conformable bandage and coating material
WO1990005144A1 (fr)	1988-11-11	1990-05-17	Medical Research Council	Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs
US5342613A (en)	1988-12-27	1994-08-30	Health Research Inc.	Pharmaceutical compositions and use thereof in the treatment of psoriasis
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US4994370A (en)	1989-01-03	1991-02-19	The United States Of America As Represented By The Department Of Health And Human Services	DNA amplification technique
PT92900A (pt)	1989-01-24	1990-07-31		Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
US5225538A (en)	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5266491A (en)	1989-03-14	1993-11-30	Mochida Pharmaceutical Co., Ltd.	DNA fragment and expression plasmid containing the DNA fragment
DE3909708A1 (de)	1989-03-23	1990-09-27	Boehringer Mannheim Gmbh	Verfahren zur herstellung bispezifischer antikoerper
ATE289350T1 (de)	1989-04-21	2005-03-15	Amgen Inc	Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
CA2016842A1 (fr)	1989-05-16	1990-11-16	Richard A. Lerner	Methode pour puiser dans le repertoire immunologique
CA2016841C (fr)	1989-05-16	1999-09-21	William D. Huse	Methode de production de polymeres ayant une activite choisie
EP0478627A4 (en)	1989-05-16	1992-08-19	William D. Huse	Co-expression of heteromeric receptors
ATE119942T1 (de)	1989-05-18	1995-04-15	Yeda Res & Dev	Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper.
ES2096590T3 (es)	1989-06-29	1997-03-16	Medarex Inc	Reactivos biespecificos para la terapia del sida.
AU640400B2 (en)	1989-08-07	1993-08-26	Peptide Technology Ltd.	Tumour necrosis factor binding ligands
ATE168416T1 (de)	1989-10-05	1998-08-15	Optein Inc	Zellfreie synthese und isolierung von genen und polypeptiden
CA2032191C (fr)	1989-12-13	1999-05-18	David Wallach	Expression de la proteine recombinante liant le facteur de necrose des tumeurs
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5580575A (en)	1989-12-22	1996-12-03	Imarx Pharmaceutical Corp.	Therapeutic drug delivery systems
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
TW212184B (fr)	1990-04-02	1993-09-01	Takeda Pharm Industry Co Ltd
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
AU8081491A (en)	1990-06-01	1991-12-31	Cetus Corporation	Compositions and methods for identifying biologically active molecules
US5723286A (en)	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
ATE204902T1 (de)	1990-06-29	2001-09-15	Large Scale Biology Corp	Melaninproduktion durch transformierte mikroorganismen
US5580734A (en)	1990-07-13	1996-12-03	Transkaryotic Therapies, Inc.	Method of producing a physical map contigous DNA sequences
CA2090126C (fr)	1990-08-02	2002-10-22	John W. Schrader	Methodes de production de proteines dotees d'une fonction desiree
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
WO1992005258A1 (fr)	1990-09-20	1992-04-02	La Trobe University	Gene encodant une enzyme de l'orge
GB9022648D0 (en)	1990-10-18	1990-11-28	Charing Cross Sunley Research	Polypeptide and its use
EP0557300B1 (fr)	1990-10-29	1997-11-19	Chiron Corporation	Anticorps bispecifiques, methodes de production et utilisation desdits anticorps
US5958413A (en)	1990-11-01	1999-09-28	Celltech Limited	Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
DE69129154T2 (de)	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5582996A (en)	1990-12-04	1996-12-10	The Wistar Institute Of Anatomy & Biology	Bifunctional antibodies and method of preparing same
GB9109645D0 (en)	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
GEP20002142B (en)	1991-01-18	2000-06-25	Amgen Inc	Method for Treatment and Prevention of TNF Mediated Diseases
JPH06508022A (ja)	1991-02-21	1994-09-14	ギリアド　サイエンシズ，インコーポレイテッド	生体分子に特異的なアプタマーおよび生産方法
US5404871A (en)	1991-03-05	1995-04-11	Aradigm	Delivery of aerosol medications for inspiration
DE69233069T2 (de)	1991-03-15	2003-11-27	Amgen Inc., Thousand Oaks	Pegylation von polypeptiden
US5656272A (en) *	1991-03-18	1997-08-12	New York University Medical Center	Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5698195A (en)	1991-03-18	1997-12-16	New York University Medical Center	Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5919452A (en)	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6284471B1 (en)	1991-03-18	2001-09-04	New York University Medical Center	Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DE10199067I2 (de)	1991-03-18	2006-03-16	Univ New York	Fuer Menschlichen Tumornekrose-Faktor spezifische Monoklonale und Chimaere Antikoerper
US6277969B1 (en)	1991-03-18	2001-08-21	New York University	Anti-TNF antibodies and peptides of human tumor necrosis factor
ATE269401T1 (de)	1991-04-10	2004-07-15	Scripps Research Inst	Bibliotheken heterodimerer rezeptoren mittels phagemiden
CA2102511A1 (fr)	1991-05-14	1992-11-15	Paul J. Higgins	Anticorps heteroconjugues pour le traitement de l'infection a vih
DE4118120A1 (de)	1991-06-03	1992-12-10	Behringwerke Ag	Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5637481A (en)	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
NL9101124A (nl)	1991-06-28	1993-01-18	Stork Brabant Bv	Rotatiezeefdrukmachine.
ES2141108T3 (es)	1991-07-02	2000-03-16	Inhale Inc	Metodo y dispositivo para proporcionar medicamentos en aerosol.
IE922437A1 (en)	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
NZ243706A (en)	1991-07-25	1994-08-26	Idec Pharma Corp	Recombinant monkey antibodies, pharmaceutical compositions
EP0525570A3 (en)	1991-07-31	1993-10-06	Miles Inc.	Anti-idiotypic antibodies that mimic tnf
IL99120A0 (en)	1991-08-07	1992-07-15	Yeda Res & Dev	Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5270170A (en)	1991-10-16	1993-12-14	Affymax Technologies N.V.	Peptide library and screening method
WO1993008829A1 (fr)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions induisant la destruction de cellules infectees par l'hiv
US5733761A (en)	1991-11-05	1998-03-31	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US5932448A (en)	1991-11-29	1999-08-03	Protein Design Labs., Inc.	Bispecific antibody heterodimers
DE69233782D1 (de)	1991-12-02	2010-05-20	Medical Res Council	Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
CA2507749C (fr)	1991-12-13	2010-08-24	Xoma Corporation	Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
US5667988A (en)	1992-01-27	1997-09-16	The Scripps Research Institute	Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE4207475A1 (de)	1992-03-10	1993-09-16	Goldwell Ag	Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung
US5447851B1 (en)	1992-04-02	1999-07-06	Univ Texas System Board Of	Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1994006498A1 (fr)	1992-09-23	1994-03-31	Fisons Plc	Inhalateur
AU5322494A (en)	1992-10-02	1994-04-26	Trustees Of Dartmouth College	Bispecific reagents for redirected targeting of low density lipoprotein
ATE174804T1 (de)	1992-10-19	1999-01-15	Dura Pharma Inc	Trockenpulverinhalator
US5643252A (en)	1992-10-28	1997-07-01	Venisect, Inc.	Laser perforator
AU5670194A (en)	1992-11-20	1994-06-22	Enzon, Inc.	Linker for linked fusion polypeptides
US5849695A (en)	1993-01-13	1998-12-15	The Regents Of The University Of California	Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
AU5883694A (en)	1993-01-19	1994-08-15	Glaxo Group Limited	Device
CN1119876A (zh)	1993-02-12	1996-04-03	莱兰斯坦福初级大学评议会	被调节的靶向基因转录及其他生物学过程
EP0614989A1 (fr)	1993-02-17	1994-09-14	MorphoSys AG	Procédé de sélection in vivo des protéines attachées des ligands
US5770428A (en)	1993-02-17	1998-06-23	Wisconsin Alumni Research Foundation	Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
US5888511A (en)	1993-02-26	1999-03-30	Advanced Biotherapy Concepts, Inc.	Treatment of autoimmune diseases, including AIDS
ES2159529T5 (es)	1993-03-05	2011-03-09	Bayer Corporation	Anticuerpos monoclonales humanos anti-tnf alfa.
CA2161351C (fr)	1993-04-26	2010-12-21	Nils Lonberg	Animaux transgeniques, pouvant produire des anticorps heterologues
GB9315846D0 (en)	1993-07-30	1993-09-15	Isis Innovation	Tumour inhibitors
US5514670A (en)	1993-08-13	1996-05-07	Pharmos Corporation	Submicron emulsions for delivery of peptides
US5625825A (en)	1993-10-21	1997-04-29	Lsi Logic Corporation	Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
DE4337197C1 (de)	1993-10-30	1994-08-25	Biotest Pharma Gmbh	Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5814599A (en)	1995-08-04	1998-09-29	Massachusetts Insitiute Of Technology	Transdermal delivery of encapsulated drugs
SE9304060D0 (sv)	1993-12-06	1993-12-06	Bioinvent Int Ab	Sätt att selektera specifika bakteriofager
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
PT749325E (pt)	1994-03-07	2002-11-29	Medarex Inc	Mpleculas biespecificas possuindo utilidades clinicas
US6190691B1 (en)	1994-04-12	2001-02-20	Adolor Corporation	Methods for treating inflammatory conditions
US5763733A (en)	1994-10-13	1998-06-09	Enzon, Inc.	Antigen-binding fusion proteins
US5549551A (en)	1994-12-22	1996-08-27	Advanced Cardiovascular Systems, Inc.	Adjustable length balloon catheter
FR2728793A1 (fr)	1994-12-28	1996-07-05	Oreal	Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6037453A (en)	1995-03-15	2000-03-14	Genentech, Inc.	Immunoglobulin variants
US5656730A (en)	1995-04-07	1997-08-12	Enzon, Inc.	Stabilized monomeric protein compositions
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5730723A (en)	1995-10-10	1998-03-24	Visionary Medical Products Corporation, Inc.	Gas pressured needle-less injection device and method
US6090382A (en) *	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
GB9526100D0 (en)	1995-12-20	1996-02-21	Intersurgical Ltd	Nebulizer
ATE209939T1 (de)	1996-01-03	2001-12-15	Glaxo Group Ltd	Inhalator
US6258562B1 (en)	1996-02-09	2001-07-10	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
DE19624387C2 (de)	1996-06-19	1999-08-19	Hatz Motoren	Kaltstartvorrichtung
ES2169299T3 (es)	1996-09-03	2002-07-01	Gsf Forschungszentrum Umwelt	Procedimiento para la destruccion de celulas tumorales contaminantes en transplantes de celulas madre utilizando anticuerpos especificos.
CA2273194C (fr)	1996-12-03	2011-02-01	Abgenix, Inc.	Mammiferes transgeniques possedant des loci de genes d'immunoglobuline dorigine humaine, dotes de regions vh et vk, et anticorps produits a partir de tels mammiferes
US5879681A (en)	1997-02-07	1999-03-09	Emisphere Technolgies Inc.	Compounds and compositions for delivering active agents
US5921447A (en)	1997-02-13	1999-07-13	Glaxo Wellcome Inc.	Flow-through metered aerosol dispensing apparatus and method of use thereof
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
IL120943A (en)	1997-05-29	2004-03-28	Univ Ben Gurion	A system for administering drugs through the skin
WO2003100013A2 (fr)	2002-05-23	2003-12-04	Cognis Corporation	C. tropicalis bloque par oxydation $g(b) non reversible
JP5470817B2 (ja)	2008-03-10	2014-04-16	日産自動車株式会社	電池用電極およびこれを用いた電池、並びにその製造方法
JP5155355B2 (ja)	2010-04-07	2013-03-06	レノボ・シンガポール・プライベート・リミテッド	無線基地局の自律的な負荷調整が可能な無線端末装置
US9619256B1 (en)	2012-06-27	2017-04-11	EMC IP Holding Company LLC	Multi site and multi tenancy
JP6136279B2 (ja)	2013-01-15	2017-05-31	株式会社ジェイテクト	転がり軸受装置
TWI503850B (zh)	2013-03-22	2015-10-11	Polytronics Technology Corp	過電流保護元件
TWI510996B (zh)	2013-10-03	2015-12-01	Acer Inc	控制觸控面板的方法以及使用該方法的可攜式電腦
US9816280B1 (en)	2016-11-02	2017-11-14	Matthew Reitnauer	Portable floor

2001
- 2001-07-08 UA UA2003021152A patent/UA81743C2/uk unknown
- 2001-08-01 US US09/920,137 patent/US7250165B2/en not_active Expired - Lifetime
- 2001-08-01 NZ NZ562811A patent/NZ562811A/en not_active IP Right Cessation
- 2001-08-07 PT PT101846301T patent/PT2330129T/pt unknown
- 2001-08-07 RS YUP-91/03A patent/RS50858B/sr unknown
- 2001-08-07 ES ES16179183T patent/ES2709335T3/es not_active Expired - Lifetime
- 2001-08-07 DK DK01957489T patent/DK1309691T3/da active
- 2001-08-07 MY MYPI20013719A patent/MY157288A/en unknown
- 2001-08-07 CN CN201010156291.5A patent/CN101980017B/zh not_active Expired - Lifetime
- 2001-08-07 AU AU7922701A patent/AU7922701A/xx active Pending
- 2001-08-07 SI SI200131069T patent/SI3118318T1/sl unknown
- 2001-08-07 LT LTEP10184630.1T patent/LT2330129T/lt unknown
- 2001-08-07 ES ES10184630.1T patent/ES2607679T3/es not_active Expired - Lifetime
- 2001-08-07 DK DK10184630.1T patent/DK2330129T3/en active
- 2001-08-07 NZ NZ524147A patent/NZ524147A/en not_active IP Right Cessation
- 2001-08-07 AU AU2001279227A patent/AU2001279227B2/en not_active Expired
- 2001-08-07 DK DK09013122.8T patent/DK2159230T3/en active
- 2001-08-07 WO PCT/US2001/024785 patent/WO2002012502A2/fr not_active Ceased
- 2001-08-07 PL PL360438A patent/PL206833B1/pl unknown
- 2001-08-07 HR HR20030089A patent/HRP20030089B1/xx not_active IP Right Cessation
- 2001-08-07 MX MXPA03001231A patent/MXPA03001231A/es active IP Right Grant
- 2001-08-07 SI SI200131036T patent/SI2159230T1/sl unknown
- 2001-08-07 CA CA2419205A patent/CA2419205C/fr not_active Expired - Lifetime
- 2001-08-07 DK DK16179183.5T patent/DK3118318T3/en active
- 2001-08-07 BR BRPI0113110A patent/BRPI0113110C8/pt active Search and Examination
- 2001-08-07 EA EA200300243A patent/EA007005B1/ru not_active IP Right Cessation
- 2001-08-07 HU HU0302376A patent/HU229523B1/hu active Protection Beyond IP Right Term
- 2001-08-07 CN CN018169600A patent/CN1468308B/zh not_active Expired - Lifetime
- 2001-08-07 ES ES01957489T patent/ES2331602T3/es not_active Expired - Lifetime
- 2001-08-07 KR KR1020037001826A patent/KR100883078B1/ko not_active Expired - Lifetime
- 2001-08-07 PT PT16179183T patent/PT3118318T/pt unknown
- 2001-08-07 MY MYPI2013001768A patent/MY157289A/en unknown
- 2001-08-07 SI SI200130948T patent/SI1309691T1/sl unknown
- 2001-08-07 EP EP16179183.5A patent/EP3118318B1/fr not_active Expired - Lifetime
- 2001-08-07 PT PT90131228T patent/PT2159230E/pt unknown
- 2001-08-07 AT AT01957489T patent/ATE446367T1/de active
- 2001-08-07 LT LTEP16179183.5T patent/LT3118318T/lt unknown
- 2001-08-07 DE DE122010000010C patent/DE122010000010I1/de active Pending
- 2001-08-07 HK HK03104875.9A patent/HK1052948B/en not_active IP Right Cessation
- 2001-08-07 EA EA200600126A patent/EA009288B1/ru not_active IP Right Cessation
- 2001-08-07 ME MEP-2008-484A patent/ME00314B/me unknown
- 2001-08-07 JP JP2002517790A patent/JP4748920B2/ja not_active Expired - Lifetime
- 2001-08-07 EP EP10184630.1A patent/EP2330129B1/fr not_active Expired - Lifetime
- 2001-08-07 SI SI200131059A patent/SI2330129T1/sl unknown
- 2001-08-07 EP EP01957489A patent/EP1309691B1/fr not_active Expired - Lifetime
- 2001-08-07 ES ES09013122.8T patent/ES2527953T3/es not_active Expired - Lifetime
- 2001-08-07 PT PT01957489T patent/PT1309691E/pt unknown
- 2001-08-07 DE DE60140259T patent/DE60140259D1/de not_active Expired - Lifetime
- 2001-08-07 IL IL15432701A patent/IL154327A0/xx unknown
- 2001-08-07 EP EP09013122.8A patent/EP2159230B1/fr not_active Expired - Lifetime
2003
- 2003-02-06 IL IL154327A patent/IL154327A/en active IP Right Grant
- 2003-02-07 NO NO20030620A patent/NO333378B1/no not_active IP Right Cessation
2004
- 2004-07-30 US US10/954,900 patent/US7691378B2/en not_active Expired - Lifetime
2005
- 2005-07-13 US US11/180,219 patent/US7521206B2/en not_active Expired - Lifetime
2008
- 2008-12-11 IL IL195898A patent/IL195898A/en active IP Right Grant
2009
- 2009-11-12 CY CY20091101189T patent/CY1109618T1/el unknown
2010
- 2010-02-01 LT LTPA2010004C patent/LTPA2010004I1/lt unknown
- 2010-03-02 BE BE2010C014C patent/BE2010C014I2/fr unknown
- 2010-03-12 LU LU91663C patent/LU91663I2/fr unknown
- 2010-03-12 FR FR10C0014C patent/FR10C0014I2/fr active Active
- 2010-04-09 CY CY2010008C patent/CY2010008I1/el unknown
2011
- 2011-04-12 JP JP2011088687A patent/JP2011188862A/ja not_active Withdrawn
2013
- 2013-06-07 NO NO2013012C patent/NO2013012I1/no unknown
2014
- 2014-03-17 HU HUS1400015C patent/HUS1400015I1/hu unknown
2015
- 2015-01-28 CY CY20151100086T patent/CY1116149T1/el unknown
- 2015-07-03 JP JP2015134150A patent/JP6449113B2/ja not_active Expired - Lifetime
2016
- 2016-12-14 CY CY20161101300T patent/CY1118443T1/el unknown
2017
- 2017-03-10 LU LU00010C patent/LUC00010I2/en unknown
- 2017-03-16 CY CY2017009C patent/CY2017009I2/el unknown
- 2017-03-20 LT LTPA2017008C patent/LTPA2017008I1/lt unknown
- 2017-08-25 NO NO2017046C patent/NO2017046I1/no unknown
- 2017-09-15 JP JP2017177751A patent/JP6564438B2/ja not_active Expired - Lifetime
2018
- 2018-11-08 JP JP2018210798A patent/JP6590428B2/ja not_active Expired - Lifetime
2019
- 2019-02-25 CY CY20191100232T patent/CY1121353T1/el unknown
- 2019-05-23 LU LU00121C patent/LUC00121I2/fr unknown
- 2019-05-27 LT LTPA2019013C patent/LTPA2019013I1/lt unknown
- 2019-05-28 CY CY2019029C patent/CY2019029I2/el unknown
- 2019-07-23 JP JP2019135600A patent/JP2019216721A/ja not_active Ceased
2020
- 2020-10-21 JP JP2020176492A patent/JP2021036872A/ja active Pending

Also Published As

Publication number	Publication date
DK3118318T3 (en)	2019-02-18
WO2002012502A3 (fr)	2002-10-31
LTPA2010004I1 (lt)	2017-03-10
NO20030620L (no)	2003-03-31
PL206833B1 (pl)	2010-09-30
PT2330129T (pt)	2016-12-28
UA81743C2 (uk)	2008-02-11
EP2330129B1 (fr)	2016-09-21
JP6449113B2 (ja)	2019-01-09
SI3118318T1 (sl)	2019-02-28
JP2016019519A (ja)	2016-02-04
LTPA2019013I1 (lt)	2019-06-25
US7691378B2 (en)	2010-04-06
JP2004523209A (ja)	2004-08-05
BRPI0113110C1 (pt)	2021-08-24
MY157288A (en)	2016-05-31
EA200600126A1 (ru)	2006-10-27
DK2159230T3 (en)	2014-11-17
NO2013012I1 (no)	2013-07-01
ATE446367T1 (de)	2009-11-15
JP2018046817A (ja)	2018-03-29
ES2709335T3 (es)	2019-04-16
HRP20030089A2 (en)	2005-02-28
EP1309691B1 (fr)	2009-10-21
CY2019029I1 (el)	2020-05-29
CN1468308B (zh)	2010-05-26
AU7922701A (en)	2002-02-18
EA009288B1 (ru)	2007-12-28
EP2330129A3 (fr)	2011-08-03
BRPI0113110C8 (pt)	2023-12-05
CN101980017B (zh)	2016-08-03
MEP48408A (en)	2011-02-10
RS50858B (sr)	2010-08-31
HU229523B1 (en)	2014-01-28
DK1309691T3 (da)	2009-12-07
IL154327A (en)	2010-06-16
US20070003548A1 (en)	2007-01-04
SI2159230T1 (sl)	2015-01-30
JP2011188862A (ja)	2011-09-29
NO20030620D0 (no)	2003-02-07
SI2330129T1 (sl)	2017-01-31
KR20030022367A (ko)	2003-03-15
LUC00121I2 (fr)	2020-01-10
MXPA03001231A (es)	2003-10-15
WO2002012502A9 (fr)	2004-03-04
US7521206B2 (en)	2009-04-21
LUC00121I1 (fr)	2019-05-27
YU9103A (sh)	2006-05-25
CY2010008I2 (el)	2012-01-25
EA007005B1 (ru)	2006-06-30
CN101980017A (zh)	2011-02-23
BR0113110A (pt)	2003-09-16
JP4748920B2 (ja)	2011-08-17
EP2159230B1 (fr)	2014-10-29
DE122010000010I1 (de)	2010-07-08
NO2017046I1 (no)	2017-08-25
CA2419205A1 (fr)	2002-02-14
EP3118318B1 (fr)	2018-12-05
WO2002012502A2 (fr)	2002-02-14
CY1118443T1 (el)	2017-06-28
LT3118318T (lt)	2019-02-11
ES2331602T3 (es)	2010-01-11
JP6590428B2 (ja)	2019-10-16
IL154327A0 (en)	2003-09-17
ME00314B (me)	2011-05-10
JP2021036872A (ja)	2021-03-11
BRPI0113110B1 (pt)	2018-03-20
JP2019054802A (ja)	2019-04-11
HUP0302376A2 (hu)	2003-10-28
FR10C0014I1 (fr)	2010-04-16
LT2330129T (lt)	2016-11-25
CY1121353T1 (el)	2020-05-29
DK2330129T3 (en)	2016-10-24
NZ524147A (en)	2005-02-25
AU2001279227B2 (en)	2007-09-20
HUP0302376A3 (en)	2012-09-28
CY2017009I1 (el)	2017-09-13
PT2159230E (pt)	2015-02-05
NO2013012I2 (no)	2013-06-07
CY1109618T1 (el)	2012-01-25
FR10C0014I2 (fr)	2011-04-01
CA2419205C (fr)	2010-10-12
CY2017009I2 (el)	2017-09-13
ES2527953T3 (es)	2015-02-02
ES2607679T3 (es)	2017-04-03
JP6564438B2 (ja)	2019-08-21
HK1140494A1 (en)	2010-10-15
CY2019029I2 (el)	2020-05-29
BE2010C014I2 (fr)	2020-12-15
IL195898A (en)	2015-11-30
KR100883078B1 (ko)	2009-02-10
MY157289A (en)	2016-05-31
LU91663I9 (fr)	2018-12-18
LUC00010I1 (fr)	2017-03-20
PT1309691E (pt)	2009-11-27
US20030049725A1 (en)	2003-03-13
NO333378B1 (no)	2013-05-21
EP2330129A2 (fr)	2011-06-08
PL360438A1 (en)	2004-09-06
EP2159230A1 (fr)	2010-03-03
CN1468308A (zh)	2004-01-14
DE60140259D1 (de)	2009-12-03
HK1052948B (en)	2010-05-07
HRP20030089B1 (hr)	2011-09-30
EA200300243A1 (ru)	2003-08-28
EP1309691A2 (fr)	2003-05-14
US20050123541A1 (en)	2005-06-09
CY2010008I1 (el)	2012-01-25
SI1309691T1 (sl)	2010-01-29
PT3118318T (pt)	2019-03-21
HK1052948A1 (en)	2003-10-03
LUC00010I2 (fr)	2017-05-30
HUS1400015I1 (hu)	2016-08-29
NZ562811A (en)	2009-05-31
EP3118318A1 (fr)	2017-01-18
CY1116149T1 (el)	2017-02-08
LTPA2017008I1 (lt)	2017-04-10
JP2019216721A (ja)	2019-12-26
US7250165B2 (en)	2007-07-31
BRPI0113110B8 (pt)	2021-05-25

Publication	Publication Date	Title
LUC00121I2 (fr)	2020-01-10
TW200716745A (en)	2007-05-01	Anti-TNF antibodies, compositions, methods and uses
MY133377A (en)	2007-11-30	Anti-il-12 antibodies, compositions, methods and uses
TW200508246A (en)	2005-03-01	Anti-dengue virus antibodies, compositions, methods and uses
WO2003047510A3 (fr)	2006-08-17	Anticorps anti-tnf, compositions, procedes et utilisations
MY171238A (en)	2019-10-04	Anti-tnf antibodies, compositions, methods and uses